Washout of small molecular contrast agent in carcinoma-derived experimental tumors.
The use of contrast-enhanced magnetic resonance imaging (MRI) for the assessment of breast carcinomas reveals satisfactory sensitivity, but due to low specificity, it does not obviate the need for subsequent tissue sampling. Its capability to differentiate benign from malignant lesion is under continuous investigation. Dynamic contrast-enhanced MRI (DCE-MRI) could improve specificity of MRI through the analysis of the kinetic of contrast enhancement. In particular, the study of the washout pattern is considered a promising tool to improve in vivo diagnosis and even to evaluate the response under chemotherapy. To provide a comprehensive characterization of this parameter in malignant tumor models, in vivo mapping of the washout of small molecular contrast agent (Gd-DTPA, molecular weight 0.57 kDa) was carried out in three transplanted/spontaneous mammary tumors, which differed in their histopathological and microvascular features. It resulted that in all models around 40% of tumor volume lacks efficient washout; washout areas are frequently, but not always, restricted to the tumor periphery and that non-washout areas are not restricted to necrotic regions. Difference in the distribution of lymphatic vessels characterized spontaneous vs. transplanted tumors but did not produce a corresponding different washout pattern, confirming that Gd-DTPA drainage does not mainly depend on lymphatic architecture. Finally, the efficiency of washout is correlated with parameters obtainable during the earlier phases of the enhancement curve and in malignant tumors it could be indirectly estimated from them.
Galiè
Mirco
M
Dip. Scienze Morfologico-Biomediche, sez. Anatomia ed Istologia, Università di Verona, Verona, Italy. paolofarace@anatomy.univr.it
Farace
Paolo
P
Merigo
Flavia
F
Fiorini
Silvia
S
Tambalo
Stefano
S
Nicolato
Elena
E
Sbarbati
Andrea
A
Marzola
Pasquina
P
D000818:Animals; D003287:Contrast Media / Q000493:pharmacokinetics*; D005260:Female; D019786:Gadolinium DTPA / Q000493:pharmacokinetics*; D042601:Lymphatic Vessels / Q000473:pathology; D008325:Mammary Neoplasms, Experimental / Q000098:blood supply / Q000175:diagnosis* / Q000276:immunology; D051379:Mice; D008815:Mice, Inbred Strains; D055806:Microvessels / Q000473:pathology; D009368:Neoplasm Transplantation; D009389:Neovascularization, Pathologic / Q000473:pathology
D003287:Contrast Media; D019786:Gadolinium DTPA